Efficacy of Silymarin in Patients With Non-alcoholic Fatty Liver Disease - The SILIVER Trial

Launched by CAMILA RIBEIRO DE AVELAR · Nov 19, 2018

Keywords

ClinConnect Summary

Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent chronic liver diseases in Brazil. It has a significantly increasing incidence today and is considered an important global health problem. It affects approximately 20 to 30% of the adult population and increases according to the severity of the risk factors. The diagnosis of this disease usually occurs in 10 to 20% of the non-obese individuals, 50% in the overweight and 80 to 90% in the obese, being twice as present in individuals with Metabolic Syndrome. Pharmacological treatment options for NAFLD are still limited and S...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults between 20 and 60 years of age, both men and women,
• • Clinical diagnosis of NAFLD, confirmed by imaging exams,
• Exclusion Criteria:
• • Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation.
• • Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification)
• • Patients with schistosomiasis;
• • Hemochromatosis
• • Wilson's disease
• • Viral or autoimmune hepatitis
• • HIV virus carriers
• • Woman who is breastfeeding
• • Users of illicit drugs
• • Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months;
• • Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months
• • Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days
• • Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or Alzheimer's disease)
• • Patients who do not participate in all stages of the research.